Skip to main content
. 2010 Sep 1;101(11):2384–2390. doi: 10.1111/j.1349-7006.2010.01684.x

Figure 3.

Figure 3

 Vascular endothelial growth factor‐C (VEGF‐C) expression in LLC cells. (A) recombinant mouse interleukin‐17 (rmIL‐17) increases VEGF‐C mRNA expression in LLC cells. Cells were stimulated with rmIL‐17 (0.1–500 ng/mL) for 6 h. The VEGF‐C mRNA expression was determined by real‐time RT‐PCR, normalized to β‐actin and expressed relative to untreated LLC cells. *P < 0.05, rmIL‐17 10 ng/mL versus untreated; **P < 0.05, rmIL‐17 100 ng/mL versus untreated. (B) rmIL‐17 induces VEGF‐C protein production by LLC cells. Cells were cultured in the presence or absence of rmIL‐17 (10 ng/mL) for 48 h. At the end of the incubation period, cell culture supernatants were collected and analyzed for VEGF‐C content by ELISA. *P < 0.05, rmIL‐17 10 ng/mL versus untreated. (C) Recombinant human IL‐17 (rhIL‐17) increases VEGF‐C mRNA expression in SPC‐A‐1 and A549 cells. Cells were stimulated with or without rhIL‐17 (10 ng/mL) for 6 h. The VEGF‐C mRNA expression was determined by real‐time RT‐PCR, normalized to ß‐actin and expressed relative to untreated SPC‐A‐1 or A549 cells. *P ≤ 0.05, rhIL‐17 10 ng/mL versus untreated. Data shown are the mean ± SD of three representative experiments.